Rigel Pharmaceuticals, Inc. (RIGL) DCF Valuation

Rigel Pharmaceuticals, Inc. (RIGL) DCF Valuation

US | Healthcare | Biotechnology | NASDAQ
Rigel Pharmaceuticals, Inc. (RIGL) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Rigel Pharmaceuticals, Inc. (RIGL) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Assess Rigel Pharmaceuticals, Inc.'s (RIGL) financial outlook like an expert! This (RIGL) DCF Calculator comes with pre-filled financials and offers complete flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 59.3 108.6 149.2 120.2 116.9 145.6 181.4 226.1 281.7 350.9
Revenue Growth, % 0 83.21 37.39 -19.43 -2.79 24.59 24.59 24.59 24.59 24.59
EBITDA -65.9 -27.7 -11.3 -53.9 -17.0 -56.0 -69.8 -87.0 -108.4 -135.0
EBITDA, % -111.11 -25.49 -7.56 -44.8 -14.53 -38.48 -38.48 -38.48 -38.48 -38.48
Depreciation .7 .7 1.2 1.0 1.2 1.3 1.6 2.0 2.5 3.1
Depreciation, % 1.15 0.64997 0.77863 0.82999 1.06 0.89396 0.89396 0.89396 0.89396 0.89396
EBIT -66.6 -28.4 -12.4 -54.9 -18.2 -57.0 -71.0 -88.5 -110.2 -137.4
EBIT, % -112.26 -26.14 -8.34 -45.63 -15.59 -39.14 -39.14 -39.14 -39.14 -39.14
Total Cash 98.1 57.3 125.0 58.2 56.9 97.2 121.1 150.8 187.9 234.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 10.1 16.0 15.5 40.3 30.6
Account Receivables, % 17.05 14.71 10.37 33.53 26.14
Inventories 1.4 1.6 6.6 9.1 5.5 6.0 7.5 9.3 11.6 14.4
Inventories, % 2.28 1.51 4.43 7.58 4.72 4.11 4.11 4.11 4.11 4.11
Accounts Payable 4.2 3.7 3.8 22.5 7.1 11.0 13.7 17.1 21.3 26.5
Accounts Payable, % 7 3.41 2.54 18.72 6.11 7.56 7.56 7.56 7.56 7.56
Capital Expenditure -1.5 -1.3 -.6 -.5 -15.0 -5.0 -6.3 -7.8 -9.7 -12.1
Capital Expenditure, % -2.45 -1.16 -0.42014 -0.37425 -12.83 -3.45 -3.45 -3.45 -3.45 -3.45
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -66.2 -29.0 -12.9 -57.7 -18.2 -56.9 -70.9 -88.4 -110.1 -137.2
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -74.3 -36.2 -16.7 -65.8 -34.0 -56.4 -81.6 -101.7 -126.7 -157.9
WACC, % 9.36 9.37 9.37 9.37 9.37 9.36 9.36 9.36 9.36 9.36
PV UFCF
SUM PV UFCF -387.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -161
Terminal Value -2,187
Present Terminal Value -1,398
Enterprise Value -1,785
Net Debt 28
Equity Value -1,813
Diluted Shares Outstanding, MM 17
Equity Value Per Share -104.18

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Rigel Pharmaceuticals’ financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template automatically computes Net Present Value (NPV) and intrinsic value for you.
  • Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
  • Built for Analysts and Investors: Perfect for testing projections, validating strategies, and optimizing your time.

Key Features

  • Customizable Financial Inputs: Adjust essential metrics such as revenue projections, R&D expenses, and operating costs.
  • Instant DCF Valuation: Automatically computes intrinsic value, net present value (NPV), and other financial metrics in real-time.
  • High-Precision Results: Leverages Rigel Pharmaceuticals' actual financial data for accurate valuation insights.
  • Effortless Scenario Testing: Easily evaluate various scenarios and analyze the resulting impacts side by side.
  • Efficiency Booster: Streamlines the valuation process, removing the need for intricate financial model development.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based RIGL DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
  3. Instant Calculations: The model automatically recalculates Rigel Pharmaceuticals' intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Utilize the outcomes to inform your investment or financial analysis.

Why Choose This Calculator for Rigel Pharmaceuticals, Inc. (RIGL)?

  • Accuracy: Utilizes authentic Rigel financial data for precise calculations.
  • Flexibility: Allows users to easily adjust and experiment with various inputs.
  • Time-Saving: Eliminate the need to create a DCF model from the ground up.
  • Professional-Grade: Crafted with the expertise and precision expected at the CFO level.
  • User-Friendly: Intuitive design ensures accessibility for users without extensive financial modeling skills.

Who Should Use Rigel Pharmaceuticals, Inc. (RIGL)?

  • Investors: Gain insights into the biotech sector with our comprehensive analysis tools.
  • Healthcare Analysts: Streamline your research with detailed reports on drug development and market potential.
  • Consultants: Tailor our resources for client presentations regarding pharmaceutical investments.
  • Biotech Enthusiasts: Enhance your knowledge of drug discovery processes and market dynamics.
  • Educators and Students: Utilize our materials as a valuable resource in life sciences and finance courses.

What the Template Contains

  • Pre-Filled DCF Model: Rigel Pharmaceuticals’ financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Rigel Pharmaceuticals’ profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.